Refinement of the equine influenza model in the natural host: A meta-analysis to determine the benefits of individual nebulisation for experimental infection and vaccine evaluation in the face of decreased strain pathogenicity

Veterinary Microbiology

Volumn 211, Issue , 2017, Pages 150-159

  Garrett, Dion ^a   Montesso, Fernando ^a   Fougerolle, Stéphanie ^b,c,d,e,h   Lopez Alvarez, Maria R ^a   Birand, Ilhan ^a   De Bock, Manuelle ^f   Huang, Chengjin M ^g   Legrand, Loïc ^b,c,d,e,h   Pronost, Stéphane ^b,c,d,e,h   Paillot, Romain ^a,b,c,d,e  

^a ANIMAL HEALTH TRUST   (United Kingdom)

^b LABEO Frank Duncombe   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d UNIVERSITÉ DE CAEN   (France)

^e La Maison du cheval   (France)

^f Elanco Animal Health Benelux   (Belgium)

^g ELANCO ANIMAL HEALTH   (United States)

^h Université de Caen Normandie   (France)

Author keywords

3Rs; Equine influenza; Horse; Nebulisation; Pathogenicity; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL TESTING REFINEMENT; ARTICLE; BODY TEMPERATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EQUINE MODEL; EXPERIMENTAL INFECTION; HORSE DISEASE; INFLUENZA A (H3N8); INFLUENZA A VIRUS (H3N8); INFLUENZA A VIRUS A/EQUINE/CAMBREMER/ 1/2012 (C/12); INFLUENZA A VIRUS A/EQUINE/EAST RENFREWSHIRE/11 (ER/11); INFLUENZA A VIRUS A/EQUINE/NORTHAMPTONSHIRE/1/13 (N/1/13); INFLUENZA A VIRUS A/EQUINE/RICHMOND/1/07 (R/07); INFLUENZA VACCINATION; NATURAL HOST; NEBULIZATION; NONHUMAN; PONY; VIROLOGY; VIRUS SHEDDING; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; HORSE; IMMUNOLOGY; META ANALYSIS; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; VACCINATION; VETERINARY;

ANIMALS; HORSE DISEASES; HORSES; INFLUENZA A VIRUS, H3N8 SUBTYPE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VIRUS SHEDDING;

EID: 85032019943     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2017.10.010     Document Type: Article

References (31)

1. Anonymous, European Pharmacopeia 9th. Monograph 0249: Equine influenza vaccine (inactivated), 2017, European Directorate for the Quality of Medicine & Health Care (EDQM), Strasbourg.
2. Atkinson, S.K., Sadofsky, L.R., Morice, A.H., How does rhinovirus cause the common cold cough. BMJ Open Respir. Res., 3, 2016, e000118.
3. Blaskovic, D., Szanto, J., Kaitancik, B., Lesso, J., Lackovic, V., Skarda, R., Experimental pathogenesis of A/equi 1 influenza virus infection in horses. Acta Virol. 10 (1966), 513–520.
4. Daly, J.M., Yates, P.J., Newton, J.R., Park, A., Henley, W., Wood, J.L., Davis-Poynter, N., Mumford, J.A., Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines. Vaccine 22 (2004), 4101–4109.
5. Fougerolle, S., Legrand, L., Lecouturier, F., Sailleau, C., Paillot, R., hans, A., Pronost, S., Genetic evolution of equne influenza virus strains (H3N8) isolated in France from 1967 to 2015 and the implications of several potential pathogenic factors. Virology 505 (2017), 210–217.
6. Heldens, J.G., Pouwels, H.G., Derks, C.G., Van de Zande, S.M., Hoeijmakers, M.J., The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap. Vaccine 27 (2009), 5530–5537.
7. Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., Altman, D.G., Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol., 8, 2010, e1000412.
8. Landolt, G., Townsend, H.G., Lunn, D.P., Equine influenza infection. Sellon, D.C., Long, M.T., (eds.) Equine Infectious Diseases, second edition, 2014, Saunders Elseiver, 141–151.
9. Legrand, L.J., Pitel, P.H., Marcillaud-Pitel, C.J., Cullinane, A.A., Courouce, A.M., Fortier, G.D., Freymuth, F.L., Pronost, S.L., Surveillance of equine influenza viruses through the RESPE network in France from November 2005 to October 2010. Equine Vet. J. 45 (2013), 776–783.
10. Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gotzsche, P.C., Devereaux, P.J., Elbourne, D., Egger, M., Altman, D.G., Consort 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, c869.
11. Mumford, J., Wood, J.M., Scott, A.M., Folkers, C., Schild, G.C., Studies with inactivated equine influenza vaccine: 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8). J. Hyg. (Lond.) 90 (1983), 385–395.
12. Mumford, J.A., Hannant, D., Jessett, D.M., Experimental infection of ponies with equine influenza (H3N8) viruses by intranasal inoculation or exposure to aerosols. Equine Vet. J. 22 (1990), 93–98.
13. Mumford, J.A., Jessett, D.M., Hannant, D., Daly, J., Uppal, P., Yadav, M.P., Webster, R.G., A model system for investigating immunity stimulated by live equine influenza vaccines. Wernery, U., Wade, J.F., Mumford, J.A., Kaaden, O.-R., (eds.) Equine Infectious Diseases VIII: Proceedings of the 8th International Conference on Equine Infectious Diseases, R&W Publications (Newmarket), Newmarket, UK, 1998, 44–49.
14. OIE, expert surveillance panel on equine influenza vaccine composition. OIE Bull., 2010, 44–45.
15. Paillot, R., El-Hage, C.M., The use of a recombinant canarypox-based equine influenza vaccine during the 2007 australian outbreak: a systematic review and summary. Pathogens, 5(42), 2016.
16. Paillot, R., Hannant, D., Kydd, J.H., Daly, J.M., Vaccination against equine influenza: quid novi. Vaccine 24 (2006), 4047–4061.
17. Paillot, R., Prowse, L., Donald, C., Medcalf, E., Montesso, F., Bryant, N., Watson, J., Jeggo, M., Elton, D., Newton, R., Trail, P., Barnes, H., Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding. Vet. Immunol. Immunopathol. 136 (2010), 272–283.
18. Paillot, R., Prowse, L., Montesso, F., Huang, C.M., Barnes, H., Escala, J., Whole inactivated equine influenza vaccine: efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity. Vet. Microbiol. 162 (2013), 396–407.
19. Paillot, R., Prowse, L., Montesso, F., Stewart, B., Jordon, L., Newton, J.R., Gilkerson, J.R., Duration of equine influenza virus shedding and infectivity in immunised horses after experimental infection with EIV A/eq2/Richmond/1/07. Vet. Microbiol. 166 (2013), 22–34.
20. Paillot, R., Fraser, S., Prowse-Davis, L., Rash, N., Montesso, F., Slootmans, N., Thomas, A., Besognet, B., Meinert, T., Ons, E., Salt, J., ISCOM-based equine influenza vaccine: duration of immunity and randomised clinical trials to assess an accelerated schedule of immunisation and efficacy. Trials Vaccinol. 4 (2015), 61–70.
21. Paillot, R., Rash, N.L., Garrett, D., Prowse-Davis, L., Montesso, F., Cullinane, A., Lemaitre, L., Thibault, J.C., Wittreck, S., Dancer, A., How to meet the last OIE expert surveillance panel recommendations on equine influenza (EI) vaccine composition: a review of the process required for the recombinant canarypox-based EI vaccine. Pathogens, 2016, 5.
22. Paillot, R., A systematic review of recent advances in equine influenza vaccination. Vaccines 2 (2014), 797–831.
23. Pouwels, H.G., Van de Zande, S.M., Horspool, L.J., Hoeijmakers, M.J., Efficacy of a non-updated, Matrix-c-based equine influenza subunit-tetanus vaccine following Florida sublineage clade 2 challenge. Vet. Rec., 174, 2014, 633.
24. Rash, A., Morton, R., Woodward, A., Maes, O., McCauley, J., Bryant, N., Elton, D., Evolution and divergence of H3N8 equine influenza viruses circulating in the United Kingdom from 2013 to 2015. Pathogens, 2017, 6.
25. Reed, L.J., Muench, H., A simple method of estimating fifty percente endpoints. Am. J. Hyg. 27 (1938), 493–497.
26. Schulz, K.F., Altman, D.G., Moher, D., Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med., 7, 2010, e1000251.
27. Smyth, G.B., Dagley, K., Tainsh, J., Insights into the economic consequences of the 2007 equine influenza outbreak in Australia. Aust. Vet. J. 89:Suppl. 1 (2011), 151–158.
28. Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S., MEGA6: molecular evolutionary genetics analysis version 6.0. Mol. Biol. Evol. 30 (2013), 2725–2729.
29. Townsend, H.G., Penner, S.J., Watts, T.C., Cook, A., Bogdan, J., Haines, D.M., Griffin, S., Chambers, T., Holland, R.E., Whitaker-Dowling, P., Youngner, J.S., Sebring, R.W., Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet. J. 33 (2001), 637–643.
30. Woodward, A.L., Rash, A.S., Blinman, D., Bowman, S., Chambers, T.M., Daly, J.M., Damiani, A., Joseph, S., Lewis, N., McCauley, J.W., Medcalf, L., Mumford, J., Newton, J.R., Tiwari, A., Bryant, N.A., Elton, D.M., Development of a surveillance scheme for equine influenza in the UK and characterisation of viruses isolated in Europe, Dubai and the USA from 2010 to 2012. Vet. Microbiol. 169 (2014), 113–127.
31. Yates, P., Mumford, J.A., Equine influenza vaccine efficacy: the significance of antigenic variation. Vet. Microbiol. 74 (2000), 173–177.